- Home
- ATOM vs DRUG Comparison
ATOM vs DRUG Comparison
Compare ATOM & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATOM
- DRUG
- Stock Information
- Founded
- ATOM 2001
- DRUG 2019
- Country
- ATOM United States
- DRUG United States
- Employees
- ATOM N/A
- DRUG N/A
- Industry
- ATOM Semiconductors
- DRUG Pharmaceuticals and Biotechnology
- Sector
- ATOM Technology
- DRUG Health Care
- Exchange
- ATOM Nasdaq
- DRUG Nasdaq
- Market Cap
- ATOM 248.9M
- DRUG 253.2M
- IPO Year
- ATOM 2016
- DRUG N/A
- Fundamental
- Price
- ATOM $5.43
- DRUG $36.06
- Analyst Decision
- ATOM Strong Buy
- DRUG Strong Buy
- Analyst Count
- ATOM 1
- DRUG 4
- Target Price
- ATOM $7.00
- DRUG $84.33
- AVG Volume (30 Days)
- ATOM 635.1K
- DRUG 50.7K
- Earning Date
- ATOM 04-24-2025
- DRUG 02-14-2025
- Dividend Yield
- ATOM N/A
- DRUG N/A
- EPS Growth
- ATOM N/A
- DRUG N/A
- EPS
- ATOM N/A
- DRUG N/A
- Revenue
- ATOM $135,000.00
- DRUG N/A
- Revenue This Year
- ATOM $580.00
- DRUG N/A
- Revenue Next Year
- ATOM N/A
- DRUG N/A
- P/E Ratio
- ATOM N/A
- DRUG N/A
- Revenue Growth
- ATOM N/A
- DRUG N/A
- 52 Week Low
- ATOM $2.31
- DRUG $0.93
- 52 Week High
- ATOM $17.55
- DRUG $79.02
- Technical
- Relative Strength Index (RSI)
- ATOM 41.05
- DRUG 49.87
- Support Level
- ATOM $5.39
- DRUG $31.55
- Resistance Level
- ATOM $6.04
- DRUG $36.25
- Average True Range (ATR)
- ATOM 0.58
- DRUG 2.74
- MACD
- ATOM 0.12
- DRUG 0.01
- Stochastic Oscillator
- ATOM 28.57
- DRUG 66.15
About ATOM Atomera Incorporated
Atomera Inc is engaged in the business of developing, commercializing, and licensing proprietary processes and technologies for the semiconductor industry. The company's technology, named Mears Silicon Technology, or MST, is a thin film of re-engineered silicon, typically 100 to 300 angstroms (or approximately 20 to 60 silicon atomic unit cells) thick. MST can be applied as a transistor channel enhancement to CMOS-type transistors, the most widely used transistor type in the semiconductor industry. The mears silicon technology of the company can be used for applications like Analog, DRAM, FinFET technology, logic and processors, and SRAM.
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.